Developer docs
API playgroundTry for free, no card

Search company profiles

Eleison Pharmaceuticals

Full company profile

uuid000962k

Namestring
Eleison Pharmaceuticals
Company typeenum
Private
Founded yearint
2009
Descriptiontext

Eleison Pharmaceuticals is a private, clinical-stage pharmaceutical company founded in 2009 and based in Princeton, New Jersey. The company acquires, develops, and commercializes clinical-stage drug candidates focused on oncology, with its lead asset being glufosfamide, an investigational chemotherapeutic agent that has completed Phase 3 clinical trials for the treatment of pancreatic cancer. As glufosfamide is not yet FDA-approved and no commercial product exists, the company is pre-revenue and operates with a small team of 1–10 employees. Its stated business model is to license or commercialize drug candidates through standard pharmaceutical channels upon regulatory clearance.

The company has no in-house AI infrastructure. Instead, it partnered with BullFrog AI to apply the bfLEAP causal AI platform to its Phase 3 glufosfamide data, and with Moffitt Cancer Center for clinical research collaboration. This combined effort applied data-driven clustering and causal analysis to identify biomarker-defined patient subgroups showing nearly threefold improvement in overall survival, reframing glufosfamide as a candidate for personalized oncology rather than a broad chemotherapy. The findings were accepted for presentation at the 2026 ASCO GI Symposium, providing third-party scientific validation of the biomarker work.

Eleison's primary end market is pancreatic cancer patients, with a secondary engagement targeting oncology drug developers through collaborative research. Its go-to-market strategy relies on traditional pharmaceutical commercialization pathways post-approval, supported by scientific dissemination via peer-reviewed publications and medical conference presentations rather than direct consumer or B2B marketing. No pricing, revenue model, or commercial channel data is disclosed, consistent with its pre-commercial clinical status.

Short descriptiontext

Eleison Pharmaceuticals is a private, clinical-stage pharmaceutical company founded in 2009 that acquires, develops, and commercializes oncology drug candidates, with its lead asset glufosfamide in Phase 3 trials for pancreatic cancer.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersPrinceton, United States
HQ citystring
Princeton
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
clinical-stage oncology drug development, pancreatic cancer therapeutics, investigational chemotherapy agents, repurposed oncology drugs, biomarker-driven patient stratification
Industry1 code
PRIMARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Oncology Pharmaceuticals
No data
Cost components4 values
Technology or R&D, Operations, Personnel, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Eleison Pharmaceuticals is a clinical-stage biopharmaceutical company that acquires, develops, and plans to commercialize drug candidates for cancer patients. Its lead asset, glufosfamide, is an investigational chemotherapeutic agent being evaluated for the treatment of pancreatic cancer. The company pairs late-stage drug development with AI-driven biomarker analytics to enable personalized oncology treatment strategies.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Nearly threefold improvement in overall survival for biomarker-identified patient subgroups in pancreatic cancer trial
+1 more record
Product overview1 text field

Eleison Pharmaceuticals is a pharmaceutical company focused on drug development for cancer treatments. Based on the available sources, the company's pipeline includes glufosfamide, an investigational chemotherapeutic agent developed for pancreatic cancer treatment. The company has conducted phase 3 clinical trials for this drug candidate. The company collaborates with technology partners like BullFrog AI for AI-driven analysis of clinical trial data to identify biomarkers and refine patient stratification for personalized oncology treatment strategies.

Product and service1 record
1Glufosfamide
CategoryOncology Pharmaceuticals
Description

An investigational chemotherapeutic agent being developed by Eleison Pharmaceuticals for the treatment of pancreatic cancer. Phase 3 clinical trial data was analyzed using causal AI to identify patient subtypes with enhanced treatment response and improved overall survival, supporting biomarker-guided personalized oncology treatment strategies.

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-09
Description

BullFrog AI's bfLEAP® causal AI platform analyzed Eleison Pharmaceuticals' Phase 3 pancreatic cancer clinical trial data for glufosfamide. The collaboration identified key biomarkers and patient subgroups showing nearly threefold improvement in overall survival. Findings were accepted for presentation at the 2026 ASCO GI Symposium. The partnership enables data-driven patient stratification and personalized treatment strategies.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-09
Description

Moffitt Cancer Center collaborated with Eleison Pharmaceuticals and BullFrog AI on the analysis of pancreatic cancer clinical trial data. The research partnership focused on using AI to identify patient subtypes responsive to glufosfamide for personalized cancer treatment strategies. Findings were presented at the 2026 ASCO GI Symposium.

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
1Rafael Pharmaceuticals
TypeDirect peer
Description

Rafael Pharmaceuticals previously developed glufosfamide and is a closely aligned clinical-stage oncology company in the same pancreatic cancer space, providing the most direct asset-level comparison for Eleison.

TypeEmerging player
Description

BullFrog AI's bfLEAP causal AI platform is the analytical engine behind Eleison's biomarker findings. While not a drug developer, it is the closest technology and operating partner and exemplifies AI-enabled clinical repositioning peers.

TypeEmerging player
Description

Lantern Pharma uses AI and genomics to reposition and develop precision oncology drug candidates, sharing Eleison's model of leveraging computational platforms to advance clinical-stage cancer assets in niche indications.

TypeEmerging player
Description

Recursion applies high-throughput biology and AI-driven drug discovery to oncology and rare diseases, representing a scaled, publicly traded peer using computational methods to accelerate clinical-stage oncology pipelines.

TypeBroad incumbent
Description

Schrödinger provides computational chemistry and AI-based drug design platforms used by multiple pharma developers, and operates its own clinical-stage oncology collaborations, making it a broad incumbent peer in AI-enabled drug development.

6Tempus AI
TypeBroad incumbent
Description

Tempus AI builds oncology-focused data and AI infrastructure for clinical and translational workflows, including biomarker identification similar in spirit to the bfLEAP analyses Eleison used to identify glufosfamide responders.

TypeEmerging player
Description

Exscientia is an AI-driven precision medicine company developing clinical-stage oncology assets, comparable to Eleison in its use of AI tooling to advance small-molecule drug candidates into the clinic.

TypeEmerging player
Description

Berg Health applies AI-driven biology to discover and develop oncology and rare disease therapeutics, sharing Eleison's positioning as a small, AI-enabled clinical-stage oncology developer.

TypeDirect peer
Description

ImmunityBio is a clinical-stage oncology company with active pancreatic cancer programs, making it a direct therapeutic-area peer even though its modality (immunotherapy) differs from glufosfamide's chemotherapy approach.

TypeBroad incumbent
Description

FibroGen is a small-cap clinical-stage biopharma with a similarly lean operational footprint developing therapeutics in oncology-adjacent specialty indications, providing a size and stage-comparable public peer benchmark.

Market position
Strengths3 records

Each record includes

Headline, Details, Source

Weaknesses3 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks4 records

Each record includes

Headline, Details, Source

Key highlights4 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Eleison Pharmaceuticals

Oncology Pharmaceuticalseleison-pharma.com

Eleison Pharmaceuticals is a private, clinical-stage pharmaceutical company founded in 2009 that acquires, develops, and commercializes oncology drug candidates, with its lead asset glufosfamide in Phase 3 trials for pancreatic cancer.

What Eleison Pharmaceuticals does

Eleison Pharmaceuticals is a private, clinical-stage pharmaceutical company founded in 2009 and based in Princeton, New Jersey. The company acquires, develops, and commercializes clinical-stage drug candidates focused on oncology, with its lead asset being glufosfamide, an investigational chemotherapeutic agent that has completed Phase 3 clinical trials for the treatment of pancreatic cancer. As glufosfamide is not yet FDA-approved and no commercial product exists, the company is pre-revenue and operates with a small team of 1–10 employees. Its stated business model is to license or commercialize drug candidates through standard pharmaceutical channels upon regulatory clearance.

The company has no in-house AI infrastructure. Instead, it partnered with BullFrog AI to apply the bfLEAP causal AI platform to its Phase 3 glufosfamide data, and with Moffitt Cancer Center for clinical research collaboration. This combined effort applied data-driven clustering and causal analysis to identify biomarker-defined patient subgroups showing nearly threefold improvement in overall survival, reframing glufosfamide as a candidate for personalized oncology rather than a broad chemotherapy. The findings were accepted for presentation at the 2026 ASCO GI Symposium, providing third-party scientific validation of the biomarker work.

Eleison's primary end market is pancreatic cancer patients, with a secondary engagement targeting oncology drug developers through collaborative research. Its go-to-market strategy relies on traditional pharmaceutical commercialization pathways post-approval, supported by scientific dissemination via peer-reviewed publications and medical conference presentations rather than direct consumer or B2B marketing. No pricing, revenue model, or commercial channel data is disclosed, consistent with its pre-commercial clinical status.

Eleison Pharmaceuticals firmographics

Firmographics
Name
Eleison Pharmaceuticals
Website
https://eleison-pharma.com
Company type
Private
Founded year
2009
Operating status
Operating
Headcount range
1–10 employees
Short description
Eleison Pharmaceuticals is a private, clinical-stage pharmaceutical company founded in 2009 that acquires, develops, and commercializes oncology drug candidates, with its lead asset glufosfamide in Phase 3 trials for pancreatic cancer.
Ownership category
akta.pro rank

Eleison Pharmaceuticals industry classification

Industry
Product category
Oncology Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Clinical-stage oncology drug development
  • Pancreatic cancer therapeutics
  • Investigational chemotherapy agents
  • Repurposed oncology drugs
  • Biomarker-driven patient stratification

Where Eleison Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Princeton
HQ country
United States
HQ region
North America

Markets served

Eleison Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Operations, Personnel, Marketing or Sales

Eleison Pharmaceuticals product offering

Product offering

Core offering

Eleison Pharmaceuticals is a clinical-stage biopharmaceutical company that acquires, develops, and plans to commercialize drug candidates for cancer patients. Its lead asset, glufosfamide, is an investigational chemotherapeutic agent being evaluated for the treatment of pancreatic cancer. The company pairs late-stage drug development with AI-driven biomarker analytics to enable personalized oncology treatment strategies.

Product overview

Eleison Pharmaceuticals is a pharmaceutical company focused on drug development for cancer treatments. Based on the available sources, the company's pipeline includes glufosfamide, an investigational chemotherapeutic agent developed for pancreatic cancer treatment. The company has conducted phase 3 clinical trials for this drug candidate. The company collaborates with technology partners like BullFrog AI for AI-driven analysis of clinical trial data to identify biomarkers and refine patient stratification for personalized oncology treatment strategies.

Differentiator

Problem solved

Functional benefit

Products and services

  • Glufosfamide An investigational chemotherapeutic agent being developed by Eleison Pharmaceuticals for the treatment of pancreatic cancer. Phase 3 clinical trial data was analyzed using causal AI to identify patient subtypes with enhanced treatment response and improved overall survival, supporting biomarker-guided personalized oncology treatment strategies.

Quantifiable outcome

  • Nearly threefold improvement in overall survival for biomarker-identified patient subgroups in pancreatic cancer trial
  • +1 more outcomes

Companies that use Eleison Pharmaceuticals

Customer profile

Segments2 records

Ideal customer profiles2 records

Eleison Pharmaceuticals technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature1 record

Eleison Pharmaceuticals partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • BullFrog AIcoreStrategic or Co-development Partner · 9 January 2026BullFrog AI's bfLEAP® causal AI platform analyzed Eleison Pharmaceuticals' Phase 3 pancreatic cancer clinical trial data for glufosfamide. The collaboration identified key biomarkers and patient subgroups showing nearly threefold improvement in overall survival. Findings were accepted for presentation at the 2026 ASCO GI Symposium. The partnership enables data-driven patient stratification and personalized treatment strategies.
  • Moffitt Cancer CentercoreStrategic or Co-development Partner · 9 January 2026Moffitt Cancer Center collaborated with Eleison Pharmaceuticals and BullFrog AI on the analysis of pancreatic cancer clinical trial data. The research partnership focused on using AI to identify patient subtypes responsive to glufosfamide for personalized cancer treatment strategies. Findings were presented at the 2026 ASCO GI Symposium.

Recent moves4 records

Expansion highlights3 records

Eleison Pharmaceuticals competitors and assessment

Company assessment

Direct peers

  • Rafael Pharmaceuticals: Rafael Pharmaceuticals previously developed glufosfamide and is a closely aligned clinical-stage oncology company in the same pancreatic cancer space, providing the most direct asset-level comparison for Eleison.
  • ImmunityBio: ImmunityBio is a clinical-stage oncology company with active pancreatic cancer programs, making it a direct therapeutic-area peer even though its modality (immunotherapy) differs from glufosfamide's chemotherapy approach.

Emerging players

  • BullFrog AI: BullFrog AI's bfLEAP causal AI platform is the analytical engine behind Eleison's biomarker findings. While not a drug developer, it is the closest technology and operating partner and exemplifies AI-enabled clinical repositioning peers.
  • Lantern Pharma: Lantern Pharma uses AI and genomics to reposition and develop precision oncology drug candidates, sharing Eleison's model of leveraging computational platforms to advance clinical-stage cancer assets in niche indications.
  • Recursion Pharmaceuticals: Recursion applies high-throughput biology and AI-driven drug discovery to oncology and rare diseases, representing a scaled, publicly traded peer using computational methods to accelerate clinical-stage oncology pipelines.
  • Exscientia: Exscientia is an AI-driven precision medicine company developing clinical-stage oncology assets, comparable to Eleison in its use of AI tooling to advance small-molecule drug candidates into the clinic.
  • Berg Health: Berg Health applies AI-driven biology to discover and develop oncology and rare disease therapeutics, sharing Eleison's positioning as a small, AI-enabled clinical-stage oncology developer.

Broad incumbents

  • Schrödinger, Inc. Schrödinger provides computational chemistry and AI-based drug design platforms used by multiple pharma developers, and operates its own clinical-stage oncology collaborations, making it a broad incumbent peer in AI-enabled drug development.
  • Tempus AI: Tempus AI builds oncology-focused data and AI infrastructure for clinical and translational workflows, including biomarker identification similar in spirit to the bfLEAP analyses Eleison used to identify glufosfamide responders.
  • FibroGen: FibroGen is a small-cap clinical-stage biopharma with a similarly lean operational footprint developing therapeutics in oncology-adjacent specialty indications, providing a size and stage-comparable public peer benchmark.

Market position

Strengths3 records

Weaknesses3 records

Competitive moat3 records

Key risks4 records

Key highlights4 records

Customer concentration

Eleison Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Eleison Pharmaceuticals leadership team

Management profile

Number of profiles

Eleison Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Eleison Pharmaceuticals M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Eleison Pharmaceuticals

What does Eleison Pharmaceuticals do?

Eleison Pharmaceuticals is a clinical-stage biopharmaceutical company that acquires, develops, and plans to commercialize drug candidates for cancer patients. Its lead asset, glufosfamide, is an investigational chemotherapeutic agent being evaluated for the treatment of pancreatic cancer. The company pairs late-stage drug development with AI-driven biomarker analytics to enable personalized oncology treatment strategies.

Is Eleison Pharmaceuticals a public or private company?

Eleison Pharmaceuticals is a private company. It is classified as unknown and is currently operating.

When was Eleison Pharmaceuticals founded?

Eleison Pharmaceuticals was founded in 2009. It employs 1 to 10 people.

Where is Eleison Pharmaceuticals based?

Eleison Pharmaceuticals is headquartered in Princeton, United States, in the North America region.

Who are Eleison Pharmaceuticals's main competitors?

Direct peers on record are Rafael Pharmaceuticals and ImmunityBio. Emerging players are BullFrog AI, Lantern Pharma, Recursion Pharmaceuticals, Exscientia and Berg Health. Broad incumbents are Schrödinger, Inc., Tempus AI and FibroGen.

Does Eleison Pharmaceuticals have an API?

No public API is recorded for Eleison Pharmaceuticals.

What industry is Eleison Pharmaceuticals in?

Eleison Pharmaceuticals's product category is Oncology Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAB, Specialty Care Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Digital JournalQ&A: Leveraging AI to assess real-world data for improved medicine performanceBullFrog AI CEO Vin Singh discussed the company's bfLEAP® causal AI platform designed to improve drug development success rates by analyzing complex biological datasets to identify disease drivers and biomarkers. The company analyzed Eleison Pharmaceuticals' phase 3 pancreatic cancer study and identified biomarkers and a patient subgroup that resulted in a nearly threefold improvement in overall survival, with findings accepted for presentation at the American Society of Clinical Oncology's Gastrointestinal Cancers Symposium. BullFrog AI also announced a new scenario-based design engine launching on March 25 to help define clinical trial strategies and build risk-balanced R&D portfolios.GlobeNewswireBullFrog AI Publishes Annual Letter to ShareholdersBullFrog AI released its 2025 annual shareholder letter, highlighting progress in technology, commercialization, and validation. The company reported a commercial collaboration with Sygnature Discovery and a real-world deployment with Eleison Pharmaceuticals, with ASCO presentation expected in January 2026. It expects continued commercialization and new partnerships in 2026.GlobeNewswireBullFrog AI Publishes Annual Letter to ShareholdersBullFrog AI Holdings, a technology-enabled drug development company using AI and machine learning, published its annual letter to shareholders highlighting 2025 progress and 2026 priorities, emphasizing its evolution from platform development to commercialization. The company reported advanced discussions with large pharmaceutical companies regarding potential out-licensing and discovery research collaborations, along with a commercial collaboration with Sygnature Discovery expected to generate significant revenue through 2028. Key milestones include a successful first real-world deployment with Eleison Pharmaceuticals in late-stage oncology development, the launch of BullFrog Data Networks™ and bfPREP™ as enterprise-grade solutions, and an upcoming presentation at the 2026 ASCO Gastrointestinal Cancers Symposium.GlobeNewswireBullFrog AI Announces Abstract Accepted for Presentation at 2026 ASCO Gastrointestinal Cancers SymposiumBullFrog AI and Eleison Pharmaceuticals accepted an abstract for the 2026 ASCO GI Symposium, presenting data-driven subtyping for pancreatic adenocarcinoma response to glufosfamide. The study uses BullFrog AI's bfLEAP and bfPREP platforms to identify patient clusters. Results will be presented in a poster session with no data disclosed until the embargo lifts.GlobeNewswireBullFrog AI Announces Abstract Accepted for Presentation at 2026 ASCO Gastrointestinal Cancers SymposiumBullFrog AI announced that an abstract submitted in collaboration with Eleison Pharmaceuticals has been accepted for presentation at the 2026 ASCO Gastrointestinal Cancers Symposium in San Francisco. The abstract, focused on data-driven precision-oncology approaches using BullFrog AI's bfLEAP® and bfPREP™ platforms, identifies patient subtypes that may demonstrate enhanced response to glufosfamide, an investigational chemotherapeutic for pancreatic cancer. The ASCO acceptance validates the company's AI technology in oncology research and underscores its growing recognition in the field.GlobeNewswireBullFrog AI’s bfPREP™ and bfLEAP® Platforms Deliver Real-World Impact in Eleison Pharmaceuticals CollaborationBullFrog AI and Eleison Pharmaceuticals are planning a joint oncology conference submission and discussing a second contract. The collaboration produced a new data ingestion module, bfPREP, which converts clinical trial PDFs into an OMOP-standardized dataset. The insights may inform trial design and market positioning.YahooBullFrog AI partners with Eleison to enhance Phase III trialBullFrog AI partnered with Eleison Pharmaceuticals to apply its AI solutions to Eleison's Phase III trial of glufosfamide for pancreatic cancer. The partnership will analyze clinical data to improve trial efficiency and patient outcomes, with the trial expected to complete by 2027. Financial terms were not disclosed.GlobeNewswireBullFrog AI and Eleison Pharmaceuticals Enter Agreement to Collaborate to Optimize Pivotal Phase 3 TrialBullFrog AI and Eleison Pharmaceuticals entered a collaboration to apply AI analytics to Eleison's Phase 3 trial of glufosfamide for pancreatic cancer. The agreement will use BullFrog's bfLEAP platform to optimize trial efficiency and patient insights, with financial terms undisclosed. Eleison expects to complete the trial in 2027.PR NewswireWindtree and Eleison Announce Initial Results of Delivering Inhaled Lipid Cisplatin (ILC) Utilizing Windtree's Drug Delivery TechnologyWindtree Therapeutics and Eleison Pharmaceuticals announced positive results from a feasibility study demonstrating that Windtree's Aerosol Delivery System (ADS) can effectively deliver Eleison's inhaled lipid cisplatin (ILC). The technology achieved higher aerosol output rates and reduced delivery time compared to conventional nebulizers, potentially improving treatment efficiency for lung cancer patients. This collaboration highlights the potential for Windtree's device platform to enhance the usability and acceptance of Eleison's oncology drug candidate.GlobeNewswireILC Granted Orphan Drug Designation in Europe for the Treatment of OsteosarcomaEleison Pharmaceuticals received European Commission orphan drug designation for ILC, an inhaled cisplatin formulation for osteosarcoma. The designation grants 10 years of marketing exclusivity and protocol assistance. The company's global phase II trial remains ongoing with interim results expected mid-year.